IMNN Profile
Imunon, Inc. is a clinical-stage biotechnology firm specializing in the creation and commercialization of innovative DNA-based immunotherapies, vaccines, and directed chemotherapies.
The company's lead product, GEN-1, is a DNA-based immunotherapy designed for the localized treatment of ovarian cancer. Another key asset, ThermoDox, is a proprietary heat-activated liposomal formulation of doxorubicin, currently being evaluated for various cancer indications.
Imunon’s pipeline also includes two feasibility-stage platform technologies aimed at advancing nucleic acid-based immunotherapies and vaccines. These platforms are focused on developing novel DNA and RNA therapies to address diverse cancer types. The company's research and development efforts are geared towards harnessing the potential of these cutting-edge technologies to improve patient outcomes in oncology.
Previously known as Celsion Corporation, Imunon rebranded in September 2022 to better reflect its strategic shift and focus on DNA-based therapeutic solutions. The company has a long history, having been established in 1982, and continues to operate from its headquarters in Lawrenceville, New Jersey.
With a commitment to advancing cancer treatment through its pioneering technologies, Imunon is positioned at the forefront of biotechnological innovation. Its ongoing clinical trials and research initiatives underscore the company’s dedication to developing effective therapies and expanding its pipeline to meet unmet medical needs in oncology.
|
